UNION therapeutics announces full-year results for 2022 and provides business update
Hellerup, Denmark, February 9, 2023, – UNION therapeutics A/S (“UNION”), a privately held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious disease, announces full-year results for the […]
UNION therapeutics announces presentation of preliminary data on Phase 2a investigator-initiated study with orismilast at the 12th EHSF Conference and provides study update
Poster presentation of preliminary data from the Phase 2a investigator-initiated study OSIRIS at the 12th EHSF Conference Hidradenitis suppurativa (HS) is a scarring, painful, inflammatory skin disease with few or […]
UNION therapeutics receives FDA Fast Track designation for oral orismilast for the treatment of moderate to severe hidradenitis suppurativa
FDA’s Fast Track designation for oral orismilast underscores the urgent need for new treatment options to fulfil the unmet medical need for people affected by moderate to severe hidradenitis suppurativa […]
UNION therapeutics announces positive topline results from the IASOS Phase 2b study of oral orismilast in patients with moderate to severe psoriasis
Primary endpoint at week 16 was met for all three active doses of oral orismilast in moderate to severe patients with psoriasis. Statistical significance reached already at the first […]
First large-scale analysis confirms that vulnerable patients remain at increased fatality to COVID-19 despite availability of vaccines
Analysis includes data from UK Kidney Association (UKKA) on 9,388 COVID-19 cases among kidney patients in the UK of which 924 were fatal (Dec 2020 to March 2022) The analyses […]
UNION therapeutics announces two peer-reviewed publications of preclinical and clinical Phase 2a data on orismilast
New insights into the pharmacological properties of orismilast and Phase 2a data published in peer-reviewed journal JEADV Data supports orismilast’s potential as a first-in-class or best-in-class treatment for a range […]
UNION therapeutics to present at the Dermatology Summit 2023
UNION invited to present orismilast at the Dermatology Summit 2023 Orismilast is a potent next-generation PDE4 inhibitor with broad anti-inflammatory properties in development as a first-in-class or best-in-class treatment for […]
UNION therapeutics and Innovent announce first subject dosed in a Chinese clinical Phase 1 study of orismilast, a novel PDE-4 inhibitor
Hellerup, Denmark and ROCKVILLE, M.D., Suzhou, China, 5 December 2022 – UNION therapeutics A/S (UNION), a privately-held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious diseases, and Innovent […]
UNION therapeutics completes 62 million DKK private placement to support clinical program
Hellerup, Denmark, 1 December 2022 – UNION therapeutics A/S (UNION), a privately-held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious diseases, today announced the completion of a […]
UNION therapeutics to present at the 6th Annual Dermatology Drug Development Summit
Data on pharmacological properties of orismilast to be presented on 2nd of November 2022 Orismilast is a potent next-generation PDE4 inhibitor with broad anti-inflammatory properties in development as a first-in-class […]
